Hopp til hovedinnhold

Laserbehandling av fødselsmerke

Noen fødselsmerker, inkludert såkalte "portvinsflekker", forsvinner ikke av seg selv, men de består og kan bli tykkere og mørkere med tiden. Laserbehandling kan da være aktuelt.

Sist revidert:

QR
Del pasientinformasjon

Den ligger åpent tilgjengelig på NHI.no sammen annen relevant informasjon

https://nhi.no/sykdommer/barn/hudlidelser/laserbehandling-av-fodselsmerke/ 

Hva er et fødselsmerke?

Laserbehandling

Kan laserbehandling ha skadevirkninger?

Vil du vite mer?

Kilder

Referanser

Dette dokumentet er basert på det profesjonelle dokumentet Infantilt hemangiom. Referanselisten for dette dokumentet vises nedenfor.

  1. Metry DW. Infantile hemangiomas: Epidemiology, pathogenesis, clinical features, and complications. UpToDate, last updated Nov 20, 2020. UpToDate 
  2. Munden A, Butschek R, Tom W, et al. Prospective study of infantile hemangiomas: Incidence, clinical characteristics, and association with placental anomalies. Br J Dermatol 2014 doi.org/10.1111/bjd.12804
  3. Léauté-Labrèze C, Hoeger P, Mazereeuw-Hautier J, et al. A randomized, controlled trial of oral propranolol in infantile hemangioma. N Engl J Med 2015; 372: 735-46. doi:10.1056/NEJMoa1404710 DOI 
  4. Tollefson MM, Frieden IJ. Early growth of infantile hemangiomas: what parents' photographs tell us. Pediatrics. 2012; 130: e314-20. doi:10.1542/peds.2011-3683 DOI 
  5. Krowchuk DP, Frieden IJ, Mancini AJ, et al. Clinical Practice Guideline for the Management of Infantile Hemangiomas. Pediatrics 2019; 143: e20183475. pmid:30584062 PubMed 
  6. Regnier S, Dupin N, Le Danff C, et al. Endothelial cells in infantile haemangiomas originate from the child and not from the mother (a fluorescence in situ hybridization-based study. Br J Dermatol 2007; 157: 158-60. pmid:17578438 PubMed 
  7. Hemangioma Investigator Group, Haggstrom AN, Drolet BA, et al. Prospective study of infantile hemangiomas: demographic, prenatal, and perinatal characteristics. J Pediatr 2007; 150: 291-4. PMID: 17307549 PubMed 
  8. Norsk barnelegeforening. Generell veileder i pediatri. Vaskulære lesjoner (hemangiomer og vaskulære malformasjoner). Sist revidert 2020. www.helsebiblioteket.no 
  9. Chang LC, Haggstrom AN, Drolet BA, et al. Growth characteristics of infantile hemangiomas: implications for management. Pediatrics 2008; 122: 360-7. pmid:18676554 PubMed 
  10. Drolet BA, Frommelt PC, Chamlin SL, et al. Initiation and use of propranolol for infantile hemangioma: report of a consensus conference. Pediatrics 2013;131:128-140 Pediatrics 
  11. Novoa M, Baselga E, Beltran S et al. Interventions for infantile haemangiomas of the skin. Cochrane Database of Systematic Reviews 2018, Issue 4. Art. No.: CD006545. DOI: 10.1002/14651858.CD006545.pub3. The Cochrane Library 
  12. Chinnadurai S, Fonnesbeck C, Snyder KM, et al. Pharmacologic Interventions for Infantile Hemangioma: A Meta-analysis. Pediatrics 2016; PMID: 26772662 PubMed 
  13. Ji Y, Chen S, Yang K et al. Efficacy and Safety of Propranolol vs Atenolol in Infants With Problematic Infantile Hemangiomas: A Randomized Clinical Trial. JAMA Otolaryngol Head Neck Surg. 2021 Apr 15. Epub ahead of print. PMID: 33856430. PubMed 
  14. Shah SD, Baselga E, McCuaig C, et al. Rebound growth of infantile hemangiomas after propranolol therapy. Pediatrics. 2016;137(4):e20151754 DOI: 10.1542/peds.2015-1754 DOI 
  15. Knöpfel N, Oesch V, Theiler M, et al. Rebound of Involuted Infantile Hemangioma After Administration of Salbutamol. Pediatrics February 2020, e20191942. doi:10.1542/peds.2019-1942 DOI 
  16. Guldbakke KK, Rørdam O, Huldt-Nystrøm T, Hanssen KH, Høivik F. Behandling av infantilt hemangiom med propranolol. Tidsskr Nor Legeforen 2010; 130: 1822-4. Tidsskrift for Den norske legeforening 
  17. Hogeling M, Adams S, Wargon O. A randomized controlled trial of propranolol for infantile hemangiomas. Pediatrics 2011; 128: e259-66. Pediatrics 
  18. Izadpanah A, Izadpanah A, Kanevsky J, et al. Propranolol versus corticosteroids in the treatment of infantile hemangioma: a systematic review and meta-analysis. Plast Reconstr Surg 2013; 131: 601-13. pmid:23142941 PubMed 
  19. Winter PR, Itinteang T, Leadbitter P, et al. PHACE syndrome--clinical features, aetiology and management. Acta Paediatr. 2016 Feb;105(2):145-53. pmid: 26469095. PubMed 
  20. Stier MF, Glick SA, Hirsch RJ. Laser treatment of pediatric vascular lesions: Port wine stains and hemangiomas. J Am Acad Dermatol 2008; 58: 261-85. PMID: 18068263 PubMed 
  21. Brightman LA, Brauer JA, Terushkin V, et al. Ablative fractional resurfacing for involuted hemangioma residuum. Arch Dermatol 2012; 148: 1294-8. pmid: 22910902 PubMed 
  22. Weibel L, Barysch MJ, Scheer HS, et al. Topical timolol for infantile hemangiomas: evidence for efficacy and degree of systemic absorption. Pediatr Dermatol. 2016;33(2):184–190